[LCID Study Number: 2016-023]
A Phase 3, Double Blind Randomized, Long Term Placebo-Controlled Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis (REGENERATE Study)
The purpose of this study is to test the effectiveness, safety and side effects of obeticholic acid (OCA) for patients with NASH. Currently, there are no therapies approved for the treatment of NASH. Obeticholic acid has not been approved for sale by the Food and Drug Administration (FDA), but it is approved for use in this study. The purpose of this study is to see if OCA is safe and effective in delaying or preventing NASH from progressing (becoming worse) in patients who have NASH and evidence of some liver fibrosis.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-3367